170 related articles for article (PubMed ID: 37611432)
21. Immunotherapy of Breast Cancer.
Criscitiello C; Curigliano G
Prog Tumor Res; 2015; 42():30-43. PubMed ID: 26377084
[TBL] [Abstract][Full Text] [Related]
22. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
[TBL] [Abstract][Full Text] [Related]
23. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
Hueman MT; Stojadinovic A; Storrer CE; Foley RJ; Gurney JM; Shriver CD; Ponniah S; Peoples GE
Breast Cancer Res Treat; 2006 Jul; 98(1):17-29. PubMed ID: 16758122
[TBL] [Abstract][Full Text] [Related]
24. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
25. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.
Woll MM; Fisher CM; Ryan GB; Gurney JM; Storrer CE; Ioannides CG; Shriver CD; Moul JW; McLeod DG; Ponniah S; Peoples GE
J Clin Immunol; 2004 Jul; 24(4):449-61. PubMed ID: 15163902
[TBL] [Abstract][Full Text] [Related]
26. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.
Schneble EJ; Berry JS; Trappey FA; Clifton GT; Ponniah S; Mittendorf E; Peoples GE
Immunotherapy; 2014; 6(5):519-31. PubMed ID: 24896623
[TBL] [Abstract][Full Text] [Related]
27. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
Patil R; Clifton GT; Holmes JP; Amin A; Carmichael MG; Gates JD; Benavides LH; Hueman MT; Ponniah S; Peoples GE
J Am Coll Surg; 2010 Feb; 210(2):140-7. PubMed ID: 20113933
[TBL] [Abstract][Full Text] [Related]
28. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.
Wiedermann U; Davis AB; Zielinski CC
Breast Cancer Res Treat; 2013 Feb; 138(1):1-12. PubMed ID: 23340862
[TBL] [Abstract][Full Text] [Related]
29. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
Gall VA; Philips AV; Qiao N; Clise-Dwyer K; Perakis AA; Zhang M; Clifton GT; Sukhumalchandra P; Ma Q; Reddy SM; Yu D; Molldrem JJ; Peoples GE; Alatrash G; Mittendorf EA
Cancer Res; 2017 Oct; 77(19):5374-5383. PubMed ID: 28819024
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.
Sanchez K; Page D; McArthur HL
Curr Probl Cancer; 2016; 40(2-4):151-162. PubMed ID: 27855963
[TBL] [Abstract][Full Text] [Related]
32. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer vaccination: Latest advances with an analytical focus on clinical trials.
Vajari MK; Sanaei MJ; Salari S; Rezvani A; Ravari MS; Bashash D
Int Immunopharmacol; 2023 Oct; 123():110696. PubMed ID: 37494841
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy in Breast Cancer.
Marmé F
Oncol Res Treat; 2016; 39(6):335-45. PubMed ID: 27260697
[TBL] [Abstract][Full Text] [Related]
35. Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
Dillman RO
Hum Vaccin Immunother; 2017 Mar; 13(3):528-532. PubMed ID: 27808593
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy in Breast Cancer- Paving New Roads?
Truica CI; Cleary AS
Curr Mol Pharmacol; 2016; 9(3):208-216. PubMed ID: 26177646
[TBL] [Abstract][Full Text] [Related]
38. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
[TBL] [Abstract][Full Text] [Related]
39. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
40. Developing an effective breast cancer vaccine.
Soliman H
Cancer Control; 2010 Jul; 17(3):183-90. PubMed ID: 20664516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
